23andMe Makes Changes to API Policy for Third-Party App Developers

Aug 24, 2018

|

NEW YORK (GenomeWeb) – Consumer genomics company 23andMe let customers know this week that it will restrict its application programming interface (API) to select third-party apps.

The firm said that in two weeks it would disable other apps' ability to access customers' 23andMe results through its API. In effect, customers that have shared their 23andMe reports with other apps through its API may no longer work.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Increased Genetic Privacy in Florida

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

Working Out the Effect

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Attention-Grabbing in Two Ways

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

Nature Papers Describe CRISPR Plant Editing Methods, DNA-PAINT Improvements, More

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

Menu

23andMe Makes Changes to API Policy for Third-Party App Developers

To read the full story....

Breaking News

CDC Combined COVID-19/Influenza Test Gets FDA Emergency Use Authorization

Agendia Settles Allegations of Medicare Fraud for $8.25M

Surge in Stocks of SARS-CoV-2 Dx Developers Pushes GenomeWeb Index Up 15 Percent in H1 2020

Translation of Dog Years Into Human Years Updated With Epigenetic Analysis

Type 2 Diabetes Associated With Altered Daily Gut Microbe Oscillations

In Brief This Week: Genomics England, Centogene, Cergentis, and More

The Scan

Increased Genetic Privacy in Florida

Working Out the Effect

Attention-Grabbing in Two Ways

Nature Papers Describe CRISPR Plant Editing Methods, DNA-PAINT Improvements, More

What's Popular?

Surge in Stocks of SARS-CoV-2 Dx Developers Pushes GenomeWeb Index Up 15 Percent in H1 2020

Centogene Gets Emergency Use Authorization for PCR-Based Coronavirus Test

Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index

FDA Issues Warning Letter to Luminex

Sherlock Biosciences, Binx Health Partner to Develop CRISPR-Based POC COVID-19 Test

Sponsorships